MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Active Stand: 2026-08-25 |
{
"resourceType" : "ConceptMap",
"id" : "mii-cm-onko-atc-transitions-2022",
"meta" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode" : "CC-BY-4.0"
},
{
"extension" : [
{
"url" : "packageId",
"valueId" : "de.medizininformatikinitiative.kerndatensatz.onkologie"
},
{
"url" : "version",
"valueString" : "2027.0.0-ballot.1"
},
{
"url" : "uri",
"valueUri" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
}
],
"url" : "http://hl7.org/fhir/StructureDefinition/package-source"
}
],
"profile" : [
🔗 "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap"🔗 ,
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"
]
},
"language" : "de",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2022</b></p><a name=\"de-mii-cm-onko-atc-transitions-2022\"> </a><a name=\"de-hcmii-cm-onko-atc-transitions-2022\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profiles: <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareableconceptmap.html\">CRMI Shareable ConceptMap</a>, <a href=\"http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishableconceptmap.html\">CRMI Publishable ConceptMap</a></p></div><p>Mapping from <a href=\"ValueSet-mii-vs-onko-systemische-therapie-substanzen-2021.html\">MII VS Onkologie Systemische Therapie Substanzen ATC 2021</a> to <a href=\"ValueSet-mii-vs-onko-systemische-therapie-substanzen-2022.html\">MII VS Onkologie Systemische Therapie Substanzen ATC 2022</a></p><br/><p>Mapping from <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc) to <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc)</p><table class=\"grid\"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td><td><b>Comment</b></td></tr><tr><td>L01XC02 (Rituximab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FA01 (Rituximab)</td><td>Reklassifizierung zu CD20-Inhibitoren</td></tr><tr><td>L01XC15 (Obinutuzumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FA03 (Obinutuzumab)</td><td>Reklassifizierung zu CD20-Inhibitoren</td></tr><tr><td>L01XC26 (Inotuzumab ozogamicin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FB01 (Inotuzumab ozogamicin)</td><td>Reklassifizierung zu CD22-Inhibitoren</td></tr><tr><td>L01XC24 (Daratumumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FC01 (Daratumumab)</td><td>Reklassifizierung zu CD38-Inhibitoren</td></tr><tr><td>L01XC03 (Trastuzumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FD01 (Trastuzumab)</td><td>Reklassifizierung zu HER2-Inhibitoren</td></tr><tr><td>L01XC13 (Pertuzumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FD02 (Pertuzumab)</td><td>Reklassifizierung zu HER2-Inhibitoren</td></tr><tr><td>L01XC14 (Trastuzumab emtansin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FD03 (Trastuzumab emtansin)</td><td>Reklassifizierung zu HER2-Inhibitoren</td></tr><tr><td>L01XC06 (Cetuximab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FE01 (Cetuximab)</td><td>Reklassifizierung zu EGFR-Inhibitoren</td></tr><tr><td>L01XC08 (Panitumumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FE02 (Panitumumab)</td><td>Reklassifizierung zu EGFR-Inhibitoren</td></tr><tr><td>L01XC17 (Nivolumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FF01 (Nivolumab)</td><td>Reklassifizierung zu PD-1-/PD-L1-Inhibitoren</td></tr><tr><td>L01XC18 (Pembrolizumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FF02 (Pembrolizumab)</td><td>Reklassifizierung zu PD-1-/PD-L1-Inhibitoren</td></tr><tr><td>L01XC28 (Durvalumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FF03 (Durvalumab)</td><td>Reklassifizierung zu PD-1-/PD-L1-Inhibitoren</td></tr><tr><td>L01XC31 (Avelumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FF04 (Avelumab)</td><td>Reklassifizierung zu PD-1-/PD-L1-Inhibitoren</td></tr><tr><td>L01XC32 (Atezolizumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FF05 (Atezolizumab)</td><td>Reklassifizierung zu PD-1-/PD-L1-Inhibitoren</td></tr><tr><td>L01XC07 (Bevacizumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FG01 (Bevacizumab)</td><td>Reklassifizierung zu VEGF-/VEGFR-Inhibitoren</td></tr><tr><td>L01XC21 (Ramucirumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FG02 (Ramucirumab)</td><td>Reklassifizierung zu VEGF-/VEGFR-Inhibitoren</td></tr><tr><td>L01XC11 (Ipilimumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FX04 (Ipilimumab)</td><td>Reklassifizierung zu andere monoklonale Antikörper</td></tr><tr><td>L01XC12 (Brentuximab vedotin)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FX05 (Brentuximab vedotin)</td><td>Reklassifizierung zu andere monoklonale Antikörper</td></tr><tr><td>L01XC19 (Blinatumomab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FX07 (Blinatumomab)</td><td>Reklassifizierung zu andere monoklonale Antikörper</td></tr><tr><td>L01XC27 (Olaratumab)</td><td><a href=\"http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent\" title=\"equivalent\">is equivalent to</a></td><td>L01FX10 (Olaratumab)</td><td>Reklassifizierung zu andere monoklonale Antikörper</td></tr></table></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "shareable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode" : "publishable"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"code" : "package",
"display" : "Package"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate" : "2026-09-15"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C3262"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"telecom" : [
{
"system" : "email",
"value" : "thomas.debertshaeuser@charite.de"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail" : {
"name" : "Taskforce Core Data Set"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "Interoperability Working Group",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail" : {
"name" : "National Steering Committee",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding" : {
"system" : "http://hl7.org/fhir/version-algorithm",
"code" : "semver",
"display" : "SemVer"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod" : {
"start" : "2027"
}
}
],
"url" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2022",
"version" : "2027.0.0-ballot.1",
"name" : "MII_CM_Onko_ATC_Transitions_2022",
"title" : "MII CM Onko ATC Code Changes 2021 to 2022",
"status" : "active",
"experimental" : false,
"date" : "2026-08-25",
"publisher" : "Medizininformatik Initiative",
"contact" : [
{
"name" : "Medizininformatik Initiative",
"telecom" : [
{
"system" : "url",
"value" : "https://www.medizininformatik-initiative.de/"
}
]
}
],
"description" : "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2021 zu 2022. In diesem Jahr erfolgte die größte Reklassifikation der onkologischen ATC-Systematik: die monoklonalen Antikörper wurden aus der Sammelgruppe L01XC in die neue, nach Zielstruktur gegliederte Gruppe L01F überführt.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "DE",
"display" : "Germany"
}
]
}
],
"purpose" : "Migration von ATC-Codes für monoklonale Antikörper, die 2022 von L01XC nach L01F umkodiert wurden.",
"sourceCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
"targetCanonical" : "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2022",
"group" : [
{
"source" : "http://fhir.de/CodeSystem/bfarm/atc",
"target" : "http://fhir.de/CodeSystem/bfarm/atc",
"element" : [
{
"code" : "L01XC02",
"display" : "Rituximab",
"target" : [
{
"code" : "L01FA01",
"display" : "Rituximab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu CD20-Inhibitoren"
}
]
},
{
"code" : "L01XC15",
"display" : "Obinutuzumab",
"target" : [
{
"code" : "L01FA03",
"display" : "Obinutuzumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu CD20-Inhibitoren"
}
]
},
{
"code" : "L01XC26",
"display" : "Inotuzumab ozogamicin",
"target" : [
{
"code" : "L01FB01",
"display" : "Inotuzumab ozogamicin",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu CD22-Inhibitoren"
}
]
},
{
"code" : "L01XC24",
"display" : "Daratumumab",
"target" : [
{
"code" : "L01FC01",
"display" : "Daratumumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu CD38-Inhibitoren"
}
]
},
{
"code" : "L01XC03",
"display" : "Trastuzumab",
"target" : [
{
"code" : "L01FD01",
"display" : "Trastuzumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu HER2-Inhibitoren"
}
]
},
{
"code" : "L01XC13",
"display" : "Pertuzumab",
"target" : [
{
"code" : "L01FD02",
"display" : "Pertuzumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu HER2-Inhibitoren"
}
]
},
{
"code" : "L01XC14",
"display" : "Trastuzumab emtansin",
"target" : [
{
"code" : "L01FD03",
"display" : "Trastuzumab emtansin",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu HER2-Inhibitoren"
}
]
},
{
"code" : "L01XC06",
"display" : "Cetuximab",
"target" : [
{
"code" : "L01FE01",
"display" : "Cetuximab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu EGFR-Inhibitoren"
}
]
},
{
"code" : "L01XC08",
"display" : "Panitumumab",
"target" : [
{
"code" : "L01FE02",
"display" : "Panitumumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu EGFR-Inhibitoren"
}
]
},
{
"code" : "L01XC17",
"display" : "Nivolumab",
"target" : [
{
"code" : "L01FF01",
"display" : "Nivolumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
}
]
},
{
"code" : "L01XC18",
"display" : "Pembrolizumab",
"target" : [
{
"code" : "L01FF02",
"display" : "Pembrolizumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
}
]
},
{
"code" : "L01XC28",
"display" : "Durvalumab",
"target" : [
{
"code" : "L01FF03",
"display" : "Durvalumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
}
]
},
{
"code" : "L01XC31",
"display" : "Avelumab",
"target" : [
{
"code" : "L01FF04",
"display" : "Avelumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
}
]
},
{
"code" : "L01XC32",
"display" : "Atezolizumab",
"target" : [
{
"code" : "L01FF05",
"display" : "Atezolizumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu PD-1-/PD-L1-Inhibitoren"
}
]
},
{
"code" : "L01XC07",
"display" : "Bevacizumab",
"target" : [
{
"code" : "L01FG01",
"display" : "Bevacizumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren"
}
]
},
{
"code" : "L01XC21",
"display" : "Ramucirumab",
"target" : [
{
"code" : "L01FG02",
"display" : "Ramucirumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu VEGF-/VEGFR-Inhibitoren"
}
]
},
{
"code" : "L01XC11",
"display" : "Ipilimumab",
"target" : [
{
"code" : "L01FX04",
"display" : "Ipilimumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu andere monoklonale Antikörper"
}
]
},
{
"code" : "L01XC12",
"display" : "Brentuximab vedotin",
"target" : [
{
"code" : "L01FX05",
"display" : "Brentuximab vedotin",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu andere monoklonale Antikörper"
}
]
},
{
"code" : "L01XC19",
"display" : "Blinatumomab",
"target" : [
{
"code" : "L01FX07",
"display" : "Blinatumomab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu andere monoklonale Antikörper"
}
]
},
{
"code" : "L01XC27",
"display" : "Olaratumab",
"target" : [
{
"code" : "L01FX10",
"display" : "Olaratumab",
"equivalence" : "equivalent",
"comment" : "Reklassifizierung zu andere monoklonale Antikörper"
}
]
}
]
}
]
}